Axolotl Biologix, an innovator in regenerative medicine technologies that improve patient outcomes with less pain and lower costs, today announced the appointment of Robert S. Kellar, Ph.D., as Chief Science Officer.Continue reading
Author Archive: AZBio
Axolotl Biologix Signs Exclusive Worldwide License for Protein Genomics’ Elastatropin®
Axolotl Biologix Signs Exclusive Worldwide License for Protein Genomics’ Elastatropin® to Drive Innovation in Regenerative Medicine Products for Wound CareContinue reading
Arizona Health Innovations
AZBio President & CEO, Joan Koerber-Walker, shares highlights of health innovations being discovered, developed and delivered in Arizona with Members of the House Health Committee in the Arizona House of Representatives on March 9, 2017.Continue reading
New indicators to aid Crohn’s disease diagnosis and treatment
The diagnosis, understanding and management of Crohn’s disease may have just received a helping hand from a joint Biodesign Institute and Mayo Clinic study aimed at developing a better blood test for the disease.
Breakthrough Lyme disease test is the ‘next generation’ of diagnostics
Crowd funding campaign launches to start clinical study for TGen-developed diagnostic testContinue reading
HTG Molecular Diagnostics Appoints New Chair of the Board of Directors
HTG Molecular Diagnostics, Inc. (Nasdaq:HTGM), a provider of instruments, reagents and services for molecular profiling applications, today announced that Ann F. Hanham, Ph.D., a director since August 2016, has been appointed to the Chair of the company’s board of directors.Continue reading
Biodesign Institute researcher a pioneer in personalized medicine field
AZBio Board Member, Joshua L. LaBaer, MD, PhD, is being honored at Founders’ Day with the Faculty Research Achievement Award for his groundbreaking work in the emerging field of personalized medicine.Continue reading
NuvOx Pharma and the University of Arkansas Initiate Phase Ib/II Clinical Trial in Stroke
NuvOx Pharma announces that the first patients have been dosed in a Phase Ib/II clinical trial for NVX-208, an oxygen therapeutic being developed for acute ischemic stroke.Continue reading